Back

The Primary Tumor Immune Microenviornment Status Predicts the Response to Immunotherapy and Overall Survival in Breast Cancer

Moorthy, A. K.; Quinn, A.

2020-07-03 cancer biology
10.1101/2020.07.03.186221 bioRxiv
Show abstract

The tumor immune microenvironment (TIME) of breast cancer is a known source of tumor heterogeneity and it has been increasingly recognized as having a role in the course of disease. In the present study, we used a computational approach to dissect the landscape of TIME states among TCGA breast cancer patients. Our central hypothesis is that the pre-existing TIME states represent a dimension which is informative about the prognosis and the response to immunotherapy. In order to test this hypothesis, we first classified breast cancer patients according to their primary TIME status. Next, we describe a TIME-based classification with prognostic value for overall survival among the TCGA patients. We further demonstrated that absolute quantification of mast cells, M0 macrophages, CD8 T cells and neutrophils were predictive of overall survival. In order to identify the TIME states which, predict response to immune checkpoint blockade, we performed a similar analysis of 11 different mouse models of primary invasive breast carcinoma that were subsequently treated with immune checkpoint inhibitor (ICI) therapy. These analyses revealed that the TIME content of M1 macrophages, monocytes and resting dendritic cells were predictive of sensitivity to ICI therapy. Taken together, these results indicate that (1) the landscape of human primary TIME states is diverse and can identify patients with more or less aggressive disease and (2) that pre-existing TIME states may be able to identify patients, of all molecular subtypes of breast cancer, who are good candidates for ICI therapy.View Full Text

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
npj Breast Cancer
23 papers in training set
Top 0.1%
18.8%
2
Breast Cancer Research
36 papers in training set
Top 0.1%
17.3%
3
Cancer Research Communications
51 papers in training set
Top 0.1%
12.1%
4
Cancers
213 papers in training set
Top 0.5%
8.0%
50% of probability mass above
5
Cancer Research
130 papers in training set
Top 1%
3.3%
6
Oncogene
85 papers in training set
Top 0.7%
2.7%
7
Clinical Cancer Research
64 papers in training set
Top 0.8%
2.5%
8
Molecular Cancer Research
49 papers in training set
Top 0.6%
1.9%
9
International Journal of Cancer
49 papers in training set
Top 0.6%
1.8%
10
The Journal of Pathology
26 papers in training set
Top 0.3%
1.8%
11
Cell Reports
1498 papers in training set
Top 19%
1.7%
12
Cancer Immunology Research
35 papers in training set
Top 0.5%
1.5%
13
BMC Cancer
67 papers in training set
Top 1%
1.5%
14
Journal for ImmunoTherapy of Cancer
75 papers in training set
Top 1%
1.4%
15
OncoImmunology
24 papers in training set
Top 0.5%
1.1%
16
Cell Reports Medicine
153 papers in training set
Top 3%
1.1%
17
PLOS Computational Biology
1863 papers in training set
Top 18%
1.1%
18
Frontiers in Immunology
638 papers in training set
Top 8%
1.1%
19
Translational Oncology
21 papers in training set
Top 0.6%
1.1%
20
Annals of Oncology
14 papers in training set
Top 0.2%
1.0%
21
Frontiers in Oncology
103 papers in training set
Top 3%
0.9%
22
Cancer Letters
35 papers in training set
Top 1%
0.9%
23
PLOS ONE
5266 papers in training set
Top 60%
0.9%
24
Scientific Reports
3612 papers in training set
Top 73%
0.9%
25
iScience
1154 papers in training set
Top 33%
0.9%
26
Science Advances
1243 papers in training set
Top 29%
0.9%
27
Molecular Oncology
55 papers in training set
Top 1%
0.9%
28
Genome Medicine
183 papers in training set
Top 6%
0.6%
29
Cellular and Molecular Bioengineering
22 papers in training set
Top 0.5%
0.6%
30
Journal of Clinical Investigation
179 papers in training set
Top 6%
0.6%